PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
Minjuvi ® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical ...
2026-08-02T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
CLASSYS Appoints Former Samsung Electronics Executive Vice President Jun-oh Yoon as CEO to Lead Its Next Stage of Global Growth
Former Samsung Group and Samsung Electronics executive who led corporate growth strategy and major global M&A initiatives across the Corporate Strategy Office and DX Division Brings extensive ...
2026-07-31T    Biotechnology   Cosmetics & Personal Care   Health Care/Hospital   Medical Equipment 
Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results
HANGZHOU, China , July 31, 2026 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products ...
2026-07-31T    Health Care/Hospital   Medical/Pharmaceuticals 
Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases RAG-1C utilizes Ractigen's ...
2026-07-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
SHANGHAI , July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") ...
2026-07-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial
HANGZHOU, China , July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in ...
2026-07-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Amorepacific Holdings Signs Strategic Investment Agreement with HIGHER Corporation on Beauty and Medical Aesthetics Collaboration
Partnership to explore solutions connecting Amorepacific's skin science with HIGHER Corporation's medical aesthetics expertise ...
2026-07-31T    Cosmetics & Personal Care   Health Care/Hospital   Household/Consumer/Cosmetics   Medical/Pharmaceuticals 
Telix H1 2026 Results: Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results ...
2026-07-31T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Kuching to Host Asia's Leading Diabetes Experts at "Diabetes Asia 2026" Conference (DAC 2026)
KUCHING, Malaysia , July 30, 2026 /PRNewswire/ -- As diabetes continues to place an increasing burden on Malaysia's healthcare system — affecting an estimated 4.75 million Malaysian adults - Kuching ...
2026-07-30T    Health Care/Hospital   Medical/Pharmaceuticals   Publishing/Information Service 
AiRISTA Receives Frost & Sullivan's 2026 North American Competitive Strategy Leadership Recognition for Healthcare Real-Time Location Solutions
The company's interoperable RTLS platform, customer-centric strategy, and continuous innovation are transforming healthcare asset management and operational efficiency. ...
2026-07-30T    Computer Software   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.